Kai Wille
Impact in
- Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematology top 10%
- Acute Myeloid Leukemia Research
Papers in
- Co-authors
- Martin Grießhammer (16 shared papers)Parvis Sadjadian (16 shared papers)Tatjana Becker (10 shared papers)Christiane Fuchs (8 shared papers)Thomas Seufferlein (7 shared papers)Lukas Perkhofer (6 shared papers)Hana Algül (5 shared papers)Andreas W. Berger (5 shared papers)
- Journals
- Journal of Clinical Oncology (5 papers)Annals of Hematology (3 papers)European Journal Of Haematology (3 papers)Clinical Research in Cardiology (2 papers)Annals of Oncology (2 papers)
- Partner nations
- GermanyAustriaUnited States
In The Last Decade
Kai Wille
34 papers receiving 351 citations
Kai Wille's Hit Papers
Peers
Comparison fields: 5 of 57
- Genetics 133
- Hematology 93
- Rheumatology 74
- Oncology 123
- Internal Medicine 12
Countries citing papers authored by Kai Wille
This map shows the geographic impact of Kai Wille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Wille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Wille more than expected).
Fields of papers citing papers by Kai Wille
This network shows the impact of papers produced by Kai Wille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Wille. The network helps show where Kai Wille may publish in the future.
Co-authors
The 25 scholars most cited alongside Kai Wille, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 58 | |
| 2 | Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). Hit paper breakdown → | 2024 | 37 |
| 3 | 2018 | 31 | |
| 4 | 2018 | 25 | |
| 5 | 2020 | 19 | |
| 6 | 2020 | 18 | |
| 7 | 2020 | 17 | |
| 8 | 2021 | 14 | |
| 9 | 2024 | 13 | |
| 10 | 2021 | 12 | |
| 11 | 2020 | 9 | |
| 12 | 2019 | 8 | |
| 13 | 2022 | 8 | |
| 14 | 2021 | 8 | |
| 15 | 2022 | 8 | |
| 16 | 2021 | 7 | |
| 17 | 2023 | 6 | |
| 18 | 2020 | 6 | |
| 19 | 2021 | 5 | |
| 20 | 2023 | 5 |
About Kai Wille
Kai Wille is a scholar working on Oncology, Genetics, Hematology, Rheumatology and Infectious Diseases, having authored 39 papers that have together received 355 indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers), Eosinophilic Disorders and Syndromes (11 papers), Chronic Myeloid Leukemia Treatments (8 papers), COVID-19 Clinical Research Studies (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Cancer Treatment and Pharmacology (5 papers), Cancer Genomics and Diagnostics (5 papers) and Acute Myeloid Leukemia Research (4 papers). The work is most often cited by research in Genetics (133 citations), Hematology (93 citations), Rheumatology (74 citations), Oncology (123 citations) and Internal Medicine (12 citations). Kai Wille has collaborated with scholars based in Germany, Austria and United States. Frequent co-authors include Martin Grießhammer, Parvis Sadjadian, Tatjana Becker, Christiane Fuchs, Thomas Seufferlein, Lukas Perkhofer, Hana Algül, Andreas W. Berger, Eike Gallmeier and Thomas J. Ettrich. Their work appears in journals such as Journal of Clinical Oncology, Annals of Hematology, European Journal Of Haematology, Clinical Research in Cardiology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.